Table 2.

Target prognostic analysis for the ITM2A expression levels in 18 pools corresponding to combinations of populations (ER and Nodal status) and clinical event criteria (MR or AE)

Nodal status	Estrogen receptor status	Event status	p-value	HR	95% CI	No. patients	No. events
Nm	ERm	AE	<  0.0001	0.75	0.68–0.82	5377	1805
Nm	ERm	MR	<  0.0001	0.7	0.62–0.80	3787	986
N-	ERm	MR	<  0.0001	0.6	0.49–0.72	1848	446
Nm	ER-	AE	<  0.0001	0.65	0.55–0.76	1517	592
N-	ER+	MR	<  0.0001	0.58	0.46–0.74	1347	302
N-	ERm	AE	< 0.0001	0.71	0.61–0.83	2384	710
Nm	ER+	AE	< 0.0001	0.78	0.69–0.87	3813	1202
Nm	ER-	MR	< 0.0001	0.63	0.51–0.79	1058	340
N-	ER+	AE	0.0001	0.69	0.57–0.83	1727	488
Nm	ER+	MR	0.0001	0.73	0.62–0.86	2700	641
N+	ERm	AE	0.0033	0.79	0.67–0.92	1483	618
N+	ER-	AE	0.0125	0.7	0.53–0.93	444	218
N-	ER-	MR	0.0301	0.68	0.48–0.96	483	142
N-	ER-	AE	0.0431	0.75	0.57–0.99	634	217
N+	ER-	MR	0.097	0.74	0.52–1.06	310	127
N+	ER+	AE	0.0997	0.84	0.69–1.03	1030	399
N+	ERm	MR	0.1606	0.85	0.68–1.06	983	323
N+	ER+	MR	0.3732	0.88	0.66–1.17	665	195

N (+, −, m) nodal status (+: positive, −: negative, m: mixed); estrogen receptor status (+: positive, −: negative, m: mixed), MR metastatic relapse, AE first pejorative event represented by any relapse or death, HR hazard ratio (values are rounded to 2 decimal places), 95% CI 95% confidence interval (values were rounded to 2 decimal places)